Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Oncology

2011

Michael Lock

Articles 1 - 2 of 2

Full-Text Articles in Medicine and Health Sciences

Brachytherapy With Permanent Gold Grain Seeds For Squamous Cell Carcinoma Of The Lip, Michael Lock Feb 2011

Brachytherapy With Permanent Gold Grain Seeds For Squamous Cell Carcinoma Of The Lip, Michael Lock

Michael Lock

Abstract PURPOSE: To describe the use of radioactive gold grain implantation for squamous cell carcinoma of the lip. METHODS: Retrospective review of 51 patients treated with permanent gold ((198)Au) grain implant brachytherapy. The seed arrangement delivered a dose of 5500 cGy at 0.5 cm from a single plane. Primary endpoints were local recurrence and cosmetic outcome. RESULTS: Median follow-up was 27 months. Median age was 69 years. The majority (90%) were T1 lesions. None of the patients had evidence of regional lymph node or distant metastasis. Twelve patients had recurrent disease with prior surgery and five patients had previous head …


A Phase Ii Trial Of Arc-Based Hypofractionated Intensity-Modulated Radiotherapy In Localized Prostate Cancer, Michael Lock Dec 2010

A Phase Ii Trial Of Arc-Based Hypofractionated Intensity-Modulated Radiotherapy In Localized Prostate Cancer, Michael Lock

Michael Lock

Abstract PURPOSE: To evaluate acute and late genitourinary (GU) and gastrointestinal (GI) toxicity and biochemical control of hypofractionated, image-guided (fiducial markers or ultrasound guidance), simplified intensity-modulated arc therapy for localized prostate cancer. METHODS AND MATERIALS: This Phase II prospective clinical trial for T1a-2cNXM0 prostate cancer enrolled 66 patients who received 63.2 Gy in 20 fractions over 4 weeks. Fiducial markers were used for image guidance in 30 patients and daily ultrasound for the remainder. Toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. RESULTS: Median follow-up was 36 months. Acute Phase Grade …